Nektar Therapeutics (NKTR) Receivables - Other (2018 - 2025)
Nektar Therapeutics (NKTR) has 7 years of Receivables - Other data on record, last reported at $1.1 million in Q4 2024.
- For Q4 2024, Receivables - Other rose 120.0% year-over-year to $1.1 million; the TTM value through Dec 2024 reached $1.1 million, up 120.0%, while the annual FY2024 figure was $1.1 million, 120.0% up from the prior year.
- Receivables - Other reached $1.1 million in Q4 2024 per NKTR's latest filing, up from $500000.0 in the prior quarter.
- Across five years, Receivables - Other topped out at $6.2 million in Q1 2020 and bottomed at $500000.0 in Q4 2023.
- Average Receivables - Other over 5 years is $3.3 million, with a median of $3.2 million recorded in 2020.
- Peak YoY movement for Receivables - Other: crashed 72.55% in 2021, then soared 120.0% in 2024.
- A 5-year view of Receivables - Other shows it stood at $5.1 million in 2020, then plummeted by 72.55% to $1.4 million in 2021, then tumbled by 50.0% to $700000.0 in 2022, then decreased by 28.57% to $500000.0 in 2023, then surged by 120.0% to $1.1 million in 2024.
- Per Business Quant database, its latest 3 readings for Receivables - Other were $1.1 million in Q4 2024, $500000.0 in Q4 2023, and $700000.0 in Q4 2022.